Reduced ability to release adenosine by diabetic rat cardiac fibroblasts due to altered expression of nucleoside transporters

Journal of Physiology

Volumn 576, Issue 1, 2006, Pages 179-189

  Podgorska, Marzena ^a   Kocbuch, Katarzyna ^a   Grden, Marzena ^a   Szutowicz, Andrzej ^a   Pawelczyk, Tadeusz ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE TRIPHOSPHATE; CONCENTRATIVE NUCLEOSIDE TRANSPORTER 1; CONCENTRATIVE NUCLEOSIDE TRANSPORTER 2; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 2; GLUCOSE; INSULIN; MEMBRANE PROTEIN; MESSENGER RNA; NUCLEOSIDE TRANSPORTER; SODIUM; UNCLASSIFIED DRUG; SODIUM ION;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVITY; ENZYME DEGRADATION; FIBROBLAST; HEART MUSCLE CELL; INSULIN RELEASE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CELL LEVEL; DISEASE ACTIVITY; MEASUREMENT; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT;

ADENOSINE; ADENOSINE TRIPHOSPHATE; ANIMALS; CARRIER PROTEINS; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; FIBROBLASTS; GENE EXPRESSION REGULATION; GLUCOSE; INSULIN; MALE; MEMBRANE TRANSPORT PROTEINS; MYOCARDIUM; NUCLEOSIDE TRANSPORT PROTEINS; RATS; RATS, WISTAR;

EID: 33748910105     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2006.111278     Document Type: Article

References (38)

1. Bell DSH (2003). Heart failure: The frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 26, 2433-2441.
2. Burgdorf C, Richardt D, Kurz T, Seyfarth M, Jain D, Katus HA & Richardt G (2001). Adenosine inhibits norepinephrine release in the postischemic rat heart: The mechanism of neuronal stunning. Cardiovasc Res 49, 713-720.
3. Camelliti P, Borg TK & Kohl P (2005). Structural and functional characterisation of cardiac fibroblasts. Cardiovasc Res 65, 40-51.
4. Chen Y, Epperson S, Makhsudova L, Ito B, Suarez J, Dillmann W & Villarreal F (2004). Functional effects of enhancing or silencing adenosine A2b receptors in cardiac fibroblasts. Am J Physiol Heart Circ Physiol 287, H2478-H2486.
5. Deussen A (2000). Metabolic flux rates of adenosine in the heart. Naunyn Schmiedebergs Arch Pharmacol 362, 351-363.
6. Deussen A, Stappert M, Schafer S & Kelm M (1999). Quantification of extracellular and intracellular adenosine production: Understanding the transmembranous concentration gradient. Circulation 99, 2041-2047.
7. Dhalla NS, Liu X, Panagia V & Takeda N (1998). Subcellular remodeling and heart dysfunction in chronic diabetes. Cardiovasc Res 40, 239-247.
8. Dubey RK, Gillespie DG & Jackson EK (1998). Adenosine inhibits collagen and protein synthesis in cardiac fibroblasts. Role of A2B receptors. Hypertension 31, 943-948.
9. Dubey RK, Gillespie DG, Mi Z & Jackson EK (1997). Exogenous and endogenous adenosine inhibits fetal calf serum-induced growth of rat cardiac fibroblasts. Role of A2B receptors. Circulation 96, 2656-2666.
10. Dubey RK, Gillespie DG, Mi Z & Jackson EK (2001a). Endogenous cyclic AMP-adenosine pathway regulates cardiac fibroblast growth. Hypertension 37, 1095-1100.
11. 2B receptors mediate the antimitogenic effects of adenosine in cardiac fibroblasts. Hypertension 37, 716-721.
12. Feldenberg LR, Thevananther S, Del Rio M, De Leon M & Devarajan P (1999). Partial ATP depletion induces Fas- and caspase-mediated apoptosis in MDCK cells. Am J Physiol 276, F837-F846.
13. Gan XT, Rajapurohitam V, Haist JV, Chidiac P, Cook MA & Karmazyn M (2005). Inhibition of phenylephrine-induced cardiomyocyte hypertrophy by activation of multiple adenosine receptor subtypes. J Pharmacol Exp Ther 312, 27-34.
14. Ghosh S, Standen NB & Galinanes M (2001). Failure to precondition pathological human myocardium. J Am Coll Cardiol 37, 711-718.
15. Hayat SA, Patel B, Khattar RS & Malik RA (2004). Diabetic cardiomyopathy: Mechanisms, diagnosis and treatment. Clin Sci 107, 539-557.
16. Kabir AMN, Cao X, Gorog DA, Tanno M, Bassi R, Bellahcene M, Quinlan RA, Davis RJ, Flavell RA, Shattock MJ & Marber MS (2005). Antimycin A induced cardioprotection is dependent on pre-ischemic p38-MAPK activation but independent of MKK3. J Mol Cell Cardiol 39, 709-717.
17. Klinger M, Freissmuth M & Nanoff C (2002). Adenosie receptors: G protein-mediated signalling and the role of accessory proteins. Cell Signal 14, 99-108.
18. +/ nucleoside cotransporter 1 (hCNT1) and role of adenosine on hCNT1 function. J Biol Chem 279, 8999-9007.
19. Lee T-M & Chou T-F (2003). Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 88, 531-537.
20. Liao Y, Takashima S, Asano Y, Asakura M, Ogai A, Shintani Y, Minamino T, Asanuma H, Sanada S, Kim J, Ogita H, Tonoike H, Hori M & Kitakaze M (2003). Activation of adenosine A1 receptor attenuates cardiac hypertrophy and prevents heart failure in murine left ventricular pressure-overload model. Circ Res 93, 759-766.
21. MacKenna D, Summerour SR & Villarreal FJ (2000). Role of mechanical factors in modulating cardiac fibroblast function and extracellular matrix synthesis. Cardiovasc Res 46, 257-263.
22. Manabe I, Shindo T & Nagai R (2002). Gene expression in fibroblasts and fibrosis. Involvement in cardiac hypertrophy. Circ Res 91, 1103-1113.
23. Moser GH, Schrader J & Deussen A (1989). Turnover of adenosine in plasma of human and dog blood. Am J Physiol 256, C799-C806.
24. Mubagwa K & Flameng W (2001). Adenosine, adenosine receptors and myocardial protection: An updated overview. Cardivasc Res 52, 25-39.
25. Pawelczyk T, Sakowicz M, Szczepanska-Konkel M & Angielski S (2000). Decreased expression of adenosine kinase in streptozotocin-induced diabetes mellitus rats. Arch Biochem Biophys 375, 1-6.
26. Pawelczyk T, Sakowicz-Burkiewicz M, Kocbuch K & Szutowicz A (2005). Differential effect of insulin and elevated glucose level on adenosine handling in rat T lymphocytes. J Cell Biochem 96, 1296-1310.
27. Pennycooke M, Chaudary N, Shuralyova I, Zhang Y & Coe IR (2001). Differential expression of human nucleoside transporters in normal and tumor tissue. Biochem Biophys Res Commun 280, 951-959.
28. +-dependent adenosine transport and altered potential for adenosine generation in diabetic cardiac myocytes. Basic Res Cardiol 101, 214-222.
29. Podgorska M, Kocbuch K & Pawelczyk T (2005). Recent advances in studies on biochemical and structural properties of equilibrative and concentrative nucleoside transporters. Acta Biochim Pol 52, 749-758.
30. Rosales OR, Eades B & Assali AR (2004). Cardiovascular drugs: adenosine role in coronary syndromes and percutaneous coronary interventions. Catheter Cardiovasc Interv 62, 358-363.
31. Rosenkranz S (2004). TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 63, 423-432.
32. + exchange to acid extrusion during anoxia in adult rat hippocampal CA1 neurons. J Neurochem 88, 594-603.
33. + transport. J Biol Chem 274, 3842-3850.
34. Swynghedauw B (1999). Molecular mechanisms of myocardial remodeling. Physiol Rev 79, 215-262.
35. Tsukamoto T & Nigam SK (1997). Tight junction proteins form large complexes and associate with the cytoskeleton in an ATP depletion model for reversible junction assembly. J Biol Chem 272, 16133-16139.
36. Van den Berghe G, Bontemps F & Hers H-G (1980). Purine catabolism in isolated rat hepatocytes. Influence of coformycin. Biochem J 188, 913-920.
37. Villarreal FJ & Kim NN (1998). Regulation of myocardial extracellular matrix components by mechanical and chemical growth factor. Cardiovasc Pathol 7, 145-151.
38. Villarreal F, Zimmermann S, Makhsudova L, Montag AC, Erion MD, Bullough D & Ito BR (2003). Modulation of cardiac remodeling by adenosine: In vitro and in vivo effects. Mol Cell Biochem 251, 17-26.